Junshi Biosciences’ marketing application for toripalimab injection (subcutaneous injection) has been accepted
March 10, 2026
Source: drugdu
30
On the evening of March 9 that Junshi Biosciences (688180) issued an announcement stating that the company received an "Acceptance Notice" issued by the National Medical Products Administration, and the marketing application for 12 indications of the company's product, toripalimab injection (subcutaneous injection), for the treatment of tumors has been accepted.
Junshi Biosciences stated that JS001sc is a subcutaneous injection formulation developed by the company based on its already marketed product, toripalimab injection. It is the first domestically produced anti-PD-1 monoclonal antibody subcutaneous injection formulation to enter the marketing application stage, and is expected to bring convenience to patients. The 12 indications listed in this marketing application for JS001sc are all the indications currently approved for toripalimab injection in mainland China.
https://finance.eastmoney.com/a/202603093666384241.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Novogene® has been approved, making its global debut in China! March 10, 2026
- CSPC indacaterol mometasone inhalation powder has been approved for clinical trials in China. March 10, 2026
- Hengrui Medicine subsidiary’s HRS9531 injection has been approved for clinical use in chronic kidney disease March 10, 2026
- ATTC Platform Shines https March 10, 2026
- Are the problems with OX40 more serious than we thought? March 10, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
